Turkey

Turkey

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
2.43 (2.31 - 2.56) 2019 Modelled IHME
2.54 (2.41 - 2.67) 2018 Modelled IHME
2.61 (2.47 - 2.76) 2017 Modelled IHME
2.65 (2.52 - 2.78) 2016 Modelled IHME
2.68 (2.54 - 2.82) 2015 Modelled IHME
2.72 (2.59 - 2.86) 2014 Modelled IHME
2.78 (2.65 - 2.92) 2013 Modelled IHME
2.84 (2.71 - 2.99) 2012 Modelled IHME
2.91 (2.76 - 3.07) 2011 Modelled IHME
2.98 (2.82 - 3.15) 2010 Modelled IHME
3.04 (2.89 - 3.21) 2009 Modelled IHME
3.11 (2.96 - 3.28) 2008 Modelled IHME
3.18 (3.03 - 3.35) 2007 Modelled IHME
3.25 (3.09 - 3.43) 2006 Modelled IHME
3.33 (3.16 - 3.52) 2005 Modelled IHME
3.41 (3.24 - 3.59) 2004 Modelled IHME
3.49 (3.32 - 3.68) 2003 Modelled IHME
3.57 (3.39 - 3.77) 2002 Modelled IHME
3.66 (3.46 - 3.88) 2001 Modelled IHME
3.75 (3.53 - 3.99) 2000 Modelled IHME
3.85 (3.61 - 4.09) 1999 Modelled IHME
3.95 (3.71 - 4.19) 1998 Modelled IHME
4.05 (3.80 - 4.29) 1997 Modelled IHME
4.14 (3.88 - 4.40) 1996 Modelled IHME
4.22 (3.95 - 4.50) 1995 Modelled IHME
4.29 (4.02 - 4.57) 1994 Modelled IHME
4.35 (4.09 - 4.62) 1993 Modelled IHME
4.41 (4.16 - 4.68) 1992 Modelled IHME
4.46 (4.19 - 4.74) 1991 Modelled IHME
4.5 (4.22 - 4.79) 1990 Modelled IHME
3 2003 Survey/reported Ozsoy MF et al, 2003
2.5 2009 Survey/reported Akcama FZ et al, 2009
2.63 (2.08 - 3.28) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.17 (0.14 - 0.20) 2019 Modelled IHME
0.18 (0.15 - 0.21) 2018 Modelled IHME
0.19 (0.16 - 0.23) 2017 Modelled IHME
0.2 (0.17 - 0.24) 2016 Modelled IHME
0.21 (0.18 - 0.25) 2015 Modelled IHME
0.22 (0.19 - 0.26) 2014 Modelled IHME
0.24 (0.20 - 0.27) 2013 Modelled IHME
0.25 (0.21 - 0.29) 2012 Modelled IHME
0.27 (0.22 - 0.31) 2011 Modelled IHME
0.29 (0.24 - 0.34) 2010 Modelled IHME
0.33 (0.27 - 0.38) 2009 Modelled IHME
0.38 (0.32 - 0.45) 2008 Modelled IHME
0.45 (0.38 - 0.53) 2007 Modelled IHME
0.53 (0.44 - 0.63) 2006 Modelled IHME
0.62 (0.52 - 0.73) 2005 Modelled IHME
0.73 (0.61 - 0.85) 2004 Modelled IHME
0.85 (0.72 - 1) 2003 Modelled IHME
1 (0.85 - 1.18) 2002 Modelled IHME
1.17 (0.99 - 1.38) 2001 Modelled IHME
1.37 (1.16 - 1.63) 2000 Modelled IHME
1.69 (1.43 - 1.98) 1999 Modelled IHME
2.15 (1.81 - 2.50) 1998 Modelled IHME
2.63 (2.20 - 3.06) 1997 Modelled IHME
3.03 (2.52 - 3.53) 1996 Modelled IHME
3.25 (2.69 - 3.81) 1995 Modelled IHME
3.34 (2.79 - 3.92) 1994 Modelled IHME
3.42 (2.85 - 4) 1993 Modelled IHME
3.47 (2.90 - 4.09) 1992 Modelled IHME
3.51 (2.92 - 4.16) 1991 Modelled IHME
3.52 (2.93 - 4.16) 1990 Modelled IHME
0.32 (0.22 - 0.48) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
42 (34 - 51) 2019 Modelled IHME
42 (34 - 51) 2018 Modelled IHME
42 (34 - 51) 2017 Modelled IHME
42 (35 - 51) 2016 Modelled IHME
43 (35 - 51) 2015 Modelled IHME
43 (35 - 51) 2014 Modelled IHME
43 (35 - 51) 2013 Modelled IHME
44 (36 - 52) 2012 Modelled IHME
44 (36 - 53) 2011 Modelled IHME
45 (37 - 54) 2010 Modelled IHME
45 (37 - 54) 2009 Modelled IHME
46 (38 - 54) 2008 Modelled IHME
47 (39 - 56) 2007 Modelled IHME
48 (40 - 57) 2006 Modelled IHME
49 (41 - 58) 2005 Modelled IHME
49 (41 - 58) 2004 Modelled IHME
49 (41 - 57) 2003 Modelled IHME
48 (40 - 57) 2002 Modelled IHME
48 (40 - 57) 2001 Modelled IHME
48 (40 - 57) 2000 Modelled IHME
48 (40 - 57) 1999 Modelled IHME
49 (40 - 57) 1998 Modelled IHME
49 (40 - 58) 1997 Modelled IHME
49 (40 - 58) 1996 Modelled IHME
49 (40 - 58) 1995 Modelled IHME
49 (40 - 58) 1994 Modelled IHME
49 (41 - 58) 1993 Modelled IHME
49 (40 - 58) 1992 Modelled IHME
49 (40 - 58) 1991 Modelled IHME
49 (40 - 58) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
99 2018 Survey/reported WHO/UNICEF
99 2017 Survey/reported WHO/UNICEF
99 2016 Survey/reported WHO/UNICEF
99 2015 Survey/reported WHO/UNICEF
99 2014 Survey/reported WHO/UNICEF
99 2013 Survey/reported WHO/UNICEF
97 2012 Survey/reported WHO/UNICEF
97 2011 Survey/reported WHO/UNICEF
97 2010 Survey/reported WHO/UNICEF
96 2009 Survey/reported WHO/UNICEF
96 2008 Survey/reported WHO/UNICEF
96 2007 Survey/reported WHO/UNICEF
95 2006 Survey/reported WHO/UNICEF
94 2005 Survey/reported WHO/UNICEF
88 2004 Survey/reported WHO/UNICEF
78 2003 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
98 2018 Survey/reported WHO/UNICEF
96 2017 Survey/reported WHO/UNICEF
98 2016 Survey/reported WHO/UNICEF
97 2015 Survey/reported WHO/UNICEF
96 2014 Survey/reported WHO/UNICEF
97 2013 Survey/reported WHO/UNICEF
97 2012 Survey/reported WHO/UNICEF
96 2011 Survey/reported WHO/UNICEF
96 2010 Survey/reported WHO/UNICEF
94 2009 Survey/reported WHO/UNICEF
92 2008 Survey/reported WHO/UNICEF
96 2007 Survey/reported WHO/UNICEF
82 2006 Survey/reported WHO/UNICEF
85 2005 Survey/reported WHO/UNICEF
77 2004 Survey/reported WHO/UNICEF
68 2003 Survey/reported WHO/UNICEF
72 2002 Survey/reported WHO/UNICEF
77 2001 Survey/reported WHO/UNICEF
71 2000 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HBV testing policy
Pregnant women, Risk-based
HepB birth dose policy
Yes
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.99 (0.82 - 1.23) 2019 Modelled IHME
0.84 (0.68 - 1.01) 2018 Modelled IHME
0.77 (0.63 - 0.91) 2017 Modelled IHME
0.78 (0.66 - 0.91) 2016 Modelled IHME
0.79 (0.68 - 0.92) 2015 Modelled IHME
0.79 (0.68 - 0.91) 2014 Modelled IHME
0.78 (0.68 - 0.90) 2013 Modelled IHME
0.77 (0.67 - 0.88) 2012 Modelled IHME
0.76 (0.66 - 0.87) 2011 Modelled IHME
0.75 (0.66 - 0.86) 2010 Modelled IHME
0.74 (0.65 - 0.84) 2009 Modelled IHME
0.73 (0.64 - 0.82) 2008 Modelled IHME
0.71 (0.63 - 0.81) 2007 Modelled IHME
0.7 (0.61 - 0.80) 2006 Modelled IHME
0.69 (0.61 - 0.79) 2005 Modelled IHME
0.69 (0.60 - 0.79) 2004 Modelled IHME
0.69 (0.59 - 0.79) 2003 Modelled IHME
0.69 (0.59 - 0.80) 2002 Modelled IHME
0.68 (0.58 - 0.80) 2001 Modelled IHME
0.68 (0.58 - 0.80) 2000 Modelled IHME
0.69 (0.59 - 0.81) 1999 Modelled IHME
0.71 (0.60 - 0.83) 1998 Modelled IHME
0.73 (0.61 - 0.86) 1997 Modelled IHME
0.76 (0.63 - 0.90) 1996 Modelled IHME
0.78 (0.65 - 0.95) 1995 Modelled IHME
0.81 (0.67 - 0.99) 1994 Modelled IHME
0.85 (0.70 - 1.04) 1993 Modelled IHME
0.89 (0.73 - 1.09) 1992 Modelled IHME
0.93 (0.76 - 1.15) 1991 Modelled IHME
0.98 (0.79 - 1.21) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
1 2009 Survey/reported Zeynep F et al, 2008.
0.3 2003 Survey/reported Ozsoy MF et al, 2003
1 (0.60 - 2.10) 2014 Modelled Gower et al, 2014
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
44.9 (41.70 - 48.20) 2015 Modelled Degenhardt L et al, 2017

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
28 (21 - 35) 2019 Modelled IHME
28 (21 - 35) 2018 Modelled IHME
28 (21 - 35) 2017 Modelled IHME
28 (21 - 34) 2016 Modelled IHME
27 (20 - 34) 2015 Modelled IHME
27 (21 - 34) 2014 Modelled IHME
27 (21 - 34) 2013 Modelled IHME
27 (20 - 34) 2012 Modelled IHME
27 (20 - 33) 2011 Modelled IHME
26 (20 - 33) 2010 Modelled IHME
26 (19 - 33) 2009 Modelled IHME
26 (19 - 33) 2008 Modelled IHME
25 (19 - 31) 2007 Modelled IHME
24 (18 - 30) 2006 Modelled IHME
23 (17 - 30) 2005 Modelled IHME
23 (17 - 29) 2004 Modelled IHME
24 (17 - 30) 2003 Modelled IHME
24 (17 - 30) 2002 Modelled IHME
24 (17 - 31) 2001 Modelled IHME
24 (17 - 30) 2000 Modelled IHME
24 (17 - 30) 1999 Modelled IHME
24 (17 - 30) 1998 Modelled IHME
24 (17 - 31) 1997 Modelled IHME
24 (17 - 31) 1996 Modelled IHME
24 (17 - 31) 1995 Modelled IHME
24 (17 - 31) 1994 Modelled IHME
24 (17 - 31) 1993 Modelled IHME
24 (18 - 31) 1992 Modelled IHME
24 (17 - 31) 1991 Modelled IHME
24 (17 - 31) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HBV testing policy
Pregnant women, Risk-based
HepB birth dose policy
Yes
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
2.43 (%)
2019
(2.31 - 2.56(%))
IHME
HCV (RNA/cAg+)
0.99 (%)
2019
(0.82 - 1.23(%))
IHME

Survey/surveillance

HBV (HBsAg+)
2.5 (%)
2009
Akcama FZ et al, 2009
HCV (anti-HCV)
1 (%)
2009
Zeynep F et al, 2008.

Hepatitis related deaths (national)

Modelled

HBV
3,530
2019
(2,645 - 4,618)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
2,624
2019
(1,910 - 3,491)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.17 (%)
2019, latest modelled
(0.14 - 0.20(%))
IHME

Prevalence PWID

HCV
44.90 (%)
2015, latest modelled
(41.70 - 48.20(%))
Degenhardt L et al, 2017

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
99 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Resources